Dexamethasone
- Generic Name
- Dexamethasone
- Brand Names
- Baycadron, Ciprodex, Decadron, Dexamethasone Intensol, Dextenza, Dioptrol, Hexadrol, Hidex 6-day Taper, Maxidex, Maxitrol, Neofordex, Ozurdex, Taperdex 12 Day Taper, Taperdex 6 Day Taper, Taperdex 7-day Taper, Tobradex, Zcort 7 Day Taper
- Drug Type
- Small Molecule
- Chemical Formula
- C22H29FO5
- CAS Number
- 50-02-2
- Unique Ingredient Identifier
- 7S5I7G3JQL
- Background
Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like hydrocortisone and prednisolone.
Dexamethasone was granted FDA approval on 30 October 1958. In a press release for the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial on 16 June 2020, dexamethasone was recommended for use in COVID-19 patients with severe respiratory symptoms. Dexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen.
- Indication
Dexamethasone and ciprofloxacin otic suspension is indicated for bacterial infections with inflammation in acute otitis media and acute otitis externa. Intramuscular and intravenous injections are indicated for a number of endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Oral tablets are indicated for the treatment of multiple myeloma. An intravitreal implant is indicated for some forms of macular edema and non-infectious posterior uveitis affecting the posterior of the eye. Various ophthalmic formulations are indicated for inflammatory conditions of the eye.
- Associated Conditions
- Acute Gouty Arthritis, Acute Leukemia, Acute Otitis Externa, Acute Otitis Media (AOM), Adrenocortical Hyperfunction, Adrenocortical Insufficiency, Allergic Conjunctivitis (AC), Alopecia Areata (AA), Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Berylliosis, Bullous dermatitis herpetiformis, Bursitis, Chorioretinitis, Choroiditis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Conjunctivitis, Contact Dermatitis, Cushing's Syndrome, Dermatitis, Diabetic Macular Edema (DME), Discoid Lupus Erythematosus (DLE), Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Episcleritis, Erythroblastopenia, Eye Infections, Eye allergy, Glaucoma, Hypercalcemia, Immune Thrombocytopenia (ITP), Infection, Inflammation, Inflammation of the External Auditory Canal, Intraocular Inflammation, Iridocyclitis, Iritis, Keloids Scars, Keratitis, Lichen Planus (LP), Lichen simplex chronicus, Loeffler's syndrome, Lymphoma, Macular Edema, Meningitis caused by Mycobacterium Tuberculosis, Middle ear inflammation, Mucosal Inflammation of the eye, Multiple Myeloma (MM), Muscle Inflammation caused by Cataract Surgery of the eye, Mycosis Fungoides (MF), Necrobiosis lipoidica diabeticorum, Non-infectious Posterior Uveitis, Ocular Infections, Irritations and Inflammations, Ocular Inflammation, Ocular Inflammation and Pain, Ocular Irritation, Ocular Itching, Ophthalmia, Sympathetic, Optic Neuritis, Otitis Externa, Pemphigus, Perennial Allergic Rhinitis (PAR), Phlyctenular keratoconjunctivitis, Postoperative Infections of the eyes caused by susceptible bacteria, Posttraumatic Osteoarthritis, Regional Enteritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Rosacea, Sarcoidosis, Scleritis, Seasonal Allergic Rhinitis, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Stevens-Johnson Syndrome, Synovitis, Systemic Lupus Erythematosus, Tenosynovitis, Trichinosis, Tuberculosis (TB), Ulcerative Colitis, Uveitis, Vernal Keratoconjunctivitis, Acquired immune hemolytic anemia, Acute rheumatic carditis, Anterior eye segment inflammation, Corticosteroid-responsive dermatoses, Ear infection-not otherwise specified caused by susceptible bacteria, Exfoliative erythroderma, Granuloma annulare lesions, Non-suppurative Thyroiditis, Ocular bacterial infections, Severe Psoriasis, Steroid-responsive inflammation of the eye, Swelling of the eyes, Varicella-zoster virus acute retinal necrosis, Watery itchy eyes
- Associated Therapies
- -
Bortezomib, Isatuximab, Cyclophosphamide and Dexamethasone Induction in Transplant-Eligible Multiple Myeloma Patients
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2020-01-27
- Last Posted Date
- 2024-01-09
- Lead Sponsor
- Medical College of Wisconsin
- Target Recruit Count
- 41
- Registration Number
- NCT04240054
- Locations
- 🇺🇸
Rush University Medical Center, Chicago, Illinois, United States
🇺🇸Froedtert Hospital & the Medical College of Wisconsin, Milwaukee, Wisconsin, United States
Therapeutic Contact Lens Drug Delivery System (TCL-DDS) in Patients With Recurrent Cystoid Macular Edema
- First Posted Date
- 2020-01-13
- Last Posted Date
- 2022-10-31
- Lead Sponsor
- Massachusetts Eye and Ear Infirmary
- Target Recruit Count
- 6
- Registration Number
- NCT04225611
- Locations
- 🇺🇸
MEEI, Boston, Massachusetts, United States
Frailty Score-guided Dosing of Lenalidomide, Dexamethasone and Daratumumab Induction Therapy
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2020-01-10
- Last Posted Date
- 2022-12-08
- Lead Sponsor
- Attaya Suvannasankha
- Registration Number
- NCT04223661
- Locations
- 🇺🇸
VA Roudebush Medical Center, Indianapolis, Indiana, United States
The Combination of ATRA and High-dose Dexamethasone as First-line Treatment in Adult Immune Thrombocytopenia
- First Posted Date
- 2020-01-03
- Last Posted Date
- 2021-09-28
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 132
- Registration Number
- NCT04217148
- Locations
- 🇨🇳
Peking University Insititute of Hematology, Peking University People's Hospital, Beijing, Beijing, China
Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm
- Conditions
- Blastic Plasmacytoid Dendritic Cell Neoplasm
- Interventions
- First Posted Date
- 2020-01-02
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT04216524
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Intraoperative Blood Pressure Management and Dexamethasone in Lung Cancer Surgery
- Conditions
- Overall SurvivalLung CancerDexamethasoneSurgeryBlood Pressure ManagementPostoperative Complications
- Interventions
- Drug: PlaceboOther: Targeted blood pressure managementDrug: DexamethasoneOther: Routine blood presure management
- First Posted Date
- 2019-12-24
- Last Posted Date
- 2022-08-09
- Lead Sponsor
- Peking University First Hospital
- Target Recruit Count
- 1988
- Registration Number
- NCT04209218
- Locations
- 🇨🇳
Department of Anesthesiology and Critical Care Medicine, Peking University First Hospital, Beijing, Beijing, China
Continuous Nerve Block Block vs Combination of Single Block Plus Intravenous Lidocaine for Postoperative Pain.
- Conditions
- Postoperative Pain
- Interventions
- Procedure: Continuous Erector Spinae Plane Nerve BlockProcedure: Single Erector Spinae Plane Nerve BlockProcedure: Continuous Quadratus Lumborum Nerve BlockProcedure: Single Quadratus Lumborum Nerve BlockDrug: Lidocaine IVDrug: Ropivacaine 0.5% Injectable SolutionDrug: LidocaineDrug: DexamethasoneDrug: Dexmedetomidine
- First Posted Date
- 2019-12-23
- Last Posted Date
- 2023-09-13
- Lead Sponsor
- Jeremy Kearns
- Target Recruit Count
- 17
- Registration Number
- NCT04208516
- Locations
- 🇺🇸
UPMC Shadyside Hospital, Pittsburgh, Pennsylvania, United States
A Trial Evaluating Patient Preference of Dropless vs Drops Post Cataract Surgery
- Conditions
- Patient Preference
- Interventions
- Other: Standard of care surgeryDrug: Dexamethasone
- First Posted Date
- 2019-12-20
- Last Posted Date
- 2019-12-20
- Lead Sponsor
- Ophthalmic Consultants of Long Island
- Target Recruit Count
- 50
- Registration Number
- NCT04205916
- Locations
- 🇺🇸
Ophthalmic Consultants of Long Island, Garden City, New York, United States
Dexamethasone-sparing Approach Including NEPA Against Emesis Caused by Cisplatin
- Conditions
- Chemotherapy-induced Nausea and Vomiting
- Interventions
- Drug: Netupitant/PalonosetronDrug: Dexamethasone
- First Posted Date
- 2019-12-17
- Last Posted Date
- 2020-04-03
- Lead Sponsor
- Consorzio Oncotech
- Target Recruit Count
- 261
- Registration Number
- NCT04201769
- Locations
- 🇮🇹
Ospedale Civile SS. Annunziata, Sassari, Italy
🇮🇹Istituto Nazionale Tumori "Regina Elena", Roma, Italy
🇮🇹Ospedale Umberto I - RAO SR, Siracusa, Italy
Study of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet
- Conditions
- Relapsed or Refractory Multiple Myeloma
- Interventions
- First Posted Date
- 2019-12-10
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Amgen
- Target Recruit Count
- 54
- Registration Number
- NCT04191616
- Locations
- 🇫🇷
Centre Hospitalier Régional Universitaire de Lille - Hôpital Claude Huriez, Lille Cedex, France
🇬🇷University Hospital of Ioannina, Ioannina, Greece
🇮🇹Azienda Unita Sanitaria Locale LE Presidio Ospedaliero Vito Fazzi Polo Oncologico Giovanni Paolo II, Lecce, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.